AlphaRx reports positive preclinical results of GAI-122 injectable nanoemulsion for Acute Ischemic Stroke

Published July 13, 2010

AlphaRx reports positive preclinical results of GAI-122 injectable nanoemulsion for Acute Ischemic Stroke
AlphaRx, Inc. announced positive preclinical results of GAI-122 injectable nanoemulsion, a Mitochondria-targeted neuroprotective drug candidate being developed for the treatment of Acute Ischemic Stroke. The results will be delivered as a podium presentation during the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon July 10 – 14, 2010.
Read more on News-Medical-Net

Lilly’s Alzheimer’s Drug Gamble Aims to Replace Billion Patent Losses
With two Alzheimer’s drugs in the final stage of human testing and two more being developed behind them, Eli Lilly & Co. is committed to one of the riskiest bets in medicine to fill a potential billion revenue gap .
Read more on Bloomberg

NICE Says No To Life Saving Treatment For Childhood Bone Cancer (1,2)
Takeda UK announces that in its draft appraisal the National Institute for Health and Clinical Excellence (NICE) does not recommend the use of Mepact® for the treatment of bone cancer (osteosarcoma) in children, adolescents and young adults.
Read more on PharmaceuticalOnline